Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.

Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.

A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.

A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.

A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Clinical Trials

Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate

Phase 2

Recruiting

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Ciprofloxacin (BAYO9867)
Drug: sodium stibogluconate (Pentostam)

First Posted Date: 2025-01-29

Last Posted Date: 2025-02-14

Lead Sponsor: Al-Mustafa University College

Target Recruit Count: 80

Registration Number: NCT06798402

Locations: 🇮🇶
Mustansiriyah University, Baghdad, Iraq

Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Phase 4

Recruiting

Conditions: Cystectomy
Bladder Cancer Requiring Cystectomy
Postoperative Infections
Antibiotic Prophylaxis
Ileal Conduit

Interventions: Drug: Pivmecillinam
Drug: Amoxicillin clavulanic acid
Drug: Amoxicillin
Drug: Cefuroxime
Drug: Ciprofloxacin
Drug: Linezolid
Drug: Nitrofurantoin
Drug: Trimethoprim
Drug: Sulfamethoxazole trimethoprim
Drug: Fluconazole

First Posted Date: 2024-11-29

Last Posted Date: 2025-01-09

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 248

Registration Number: NCT06709196

Locations: 🇩🇰
Department of Urology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Department of Urology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Department of Urology, Rigshospitalet, Copenhagen, Denmark

and more 2 locations

Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing

Phase 2

Active, not recruiting

Conditions: Periapical Disease

Interventions: Drug: Ciprofloxacin 500 mg +ibuprofen 400mg
Drug: Curcumin Gel
Drug: Metapaste [calcium hydroxide paste (control group)]
Drug: nanocurcumin gel

First Posted Date: 2024-04-02

Last Posted Date: 2024-08-20

Lead Sponsor: Ain Shams University

Target Recruit Count: 80

Registration Number: NCT06342830

Locations: 🇪🇬
faculty of dentistry, Ain shams university, Cairo, Egypt

Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin

Phase 3

Completed

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Ciprofloxacin 750 MG
Drug: Rifaximin 550Mg Tab
Diagnostic Test: ascitic fluid sample

First Posted Date: 2024-01-31

Last Posted Date: 2024-01-31

Lead Sponsor: Ain Shams University

Target Recruit Count: 80

Registration Number: NCT06234046

Locations: 🇪🇬
Mostafa Elfors, Cairo, Egypt

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1

Recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions: Drug: Enzalutamide 40mg
Drug: Amoxicillin 500mg
Drug: Metronidazole 400mg
Drug: Vancomycin 125mg
Drug: Ciprofloxacin 500g

First Posted Date: 2023-11-13

Last Posted Date: 2025-04-24

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 39

Registration Number: NCT06126731

Locations: 🇨🇭
Oncolgy Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
🇬🇧
The Royal Marsden NHS Foundation Trust, London Borough of Sutton, United Kingdom

Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Phase 4

Recruiting

Conditions: Bronchiectasis Adult
Pseudomonas Aeruginosa Infection

Interventions: Drug: Tobramycin Inhalant Product
Drug: Oral ciprofloxacin placebo
Drug: Natural saline inhalation
Drug: Ciprofloxacin 750 MG

First Posted Date: 2023-10-23

Last Posted Date: 2024-12-18

Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Target Recruit Count: 364

Registration Number: NCT06093191

Locations: 🇨🇳
The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
🇨🇳
Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shangdong, China

and more 60 locations